<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>FRAGMENTA: End-to-end Fragmentation-based Generative Model with Agentic Tuning for Drug Lead Optimization - Health AI Hub</title>
    <meta name="description" content="FRAGMENTA is an end-to-end framework for drug lead optimization designed to overcome challenges of sparse datasets and slow model tuning. It integrates a novel ">
    <link rel="icon" type="image/svg+xml" href="../favicon.svg">
    <link rel="icon" type="image/png" sizes="32x32" href="../favicon-32x32.png">
    <link rel="icon" type="image/png" sizes="16x16" href="../favicon-16x16.png">
    <link rel="stylesheet" href="../styles.css">
</head>
<body>
    <header>
        <div class="container">
            <div class="breadcrumb">
                <a href="../index.html">‚Üê Back to all papers</a>
                <a href="../index.html" class="home-btn">üè† Home</a>
            </div>
        </div>
    </header>

    <main class="container paper-detail">
        <article>
            <h1>FRAGMENTA: End-to-end Fragmentation-based Generative Model with Agentic Tuning for Drug Lead Optimization</h1>

            <div class="paper-metadata">
                <div class="meta-row">
                    <strong>arXiv ID:</strong> <a href="http://arxiv.org/abs/2511.20510v2" target="_blank">2511.20510v2</a>
                </div>
                <div class="meta-row">
                    <strong>Published:</strong> 2025-11-25
                </div>
                <div class="meta-row">
                    <strong>Authors:</strong> Yuto Suzuki, Paul Awolade, Daniel V. LaBarbera, Farnoush Banaei-Kashani
                </div>
                <div class="meta-row">
                    <strong>Categories:</strong> cs.AI
                </div>
                <div class="meta-row">
                    <strong>Relevance Score:</strong> 0.95 / 1.00
                </div>
            </div>

            <div class="action-buttons">
                <a href="http://arxiv.org/abs/2511.20510v2" target="_blank" class="btn btn-primary">View on arXiv</a>
                <a href="https://arxiv.org/pdf/2511.20510v2" target="_blank" class="btn btn-primary">Download PDF</a>
            </div>

            <section class="paper-section">
                <h2>Summary</h2>
                <p class="summary-text">FRAGMENTA is an end-to-end framework for drug lead optimization designed to overcome challenges of sparse datasets and slow model tuning. It integrates a novel generative model that uses dynamic Q-learning for joint fragmentation and generation, alongside an agentic AI system that automates objective refinement via conversational expert feedback. This approach significantly outperformed baselines in cancer drug discovery, with the fully autonomous Agent-Agent system surpassing traditional human-human tuning.</p>
            </section>

            <section class="paper-section">
                <h2>Medical Relevance</h2>
                <p>This research is crucial for accelerating early-stage drug discovery by improving the efficiency and effectiveness of generating and optimizing novel chemical compounds, which can lead to faster development of new therapies for various diseases, including cancer.</p>
            </section>

            
            <section class="paper-section">
                <h2>AI Health Application</h2>
                <p>The paper presents a generative AI model (FRAGMENTA) for de novo molecule design and optimization, crucial for identifying potential drug candidates. It also introduces an agentic AI system designed to automate and enhance the drug development process by learning from domain experts, thereby accelerating drug lead optimization and reducing the need for direct AI engineering intervention. This specifically applies to discovering new treatments, exemplified by its use in cancer drug discovery.</p>
            </section>
            

            <section class="paper-section">
                <h2>Key Points</h2>
                <ul class="key-points">
                    
                    <li>Addresses critical limitations in molecule generation for drug discovery: sparse class-specific datasets (<100 examples) and current fragment-based models' heuristic fragmentation leading to limited diversity.</li>
                    
                    <li>Introduces a novel generative model component that redefines molecular fragmentation as a "vocabulary selection" problem, employing dynamic Q-learning to jointly optimize both fragmentation and molecule generation.</li>
                    
                    <li>Features an innovative agentic AI system designed to refine drug optimization objectives through direct conversational feedback from domain experts, effectively removing the AI engineer from the model tuning loop.</li>
                    
                    <li>The agentic system is engineered to progressively acquire and integrate domain-specific knowledge, moving towards fully autonomous and intelligent model tuning.</li>
                    
                    <li>In real-world cancer drug discovery experiments, FRAGMENTA's Human-Agent configuration identified nearly twice as many high-scoring molecules compared to existing baseline methods.</li>
                    
                    <li>The fully autonomous Agent-Agent system demonstrated superior performance, outperforming traditional Human-Human tuning setups, highlighting its efficacy in accurately capturing and implementing expert intent.</li>
                    
                    <li>The framework's success underscores the potential of integrating advanced generative AI with autonomous agentic systems to significantly enhance the speed and efficiency of drug lead optimization.</li>
                    
                </ul>
            </section>

            <div class="two-column">
                <section class="paper-section">
                    <h2>Methodology</h2>
                    <p>FRAGMENTA comprises a novel generative model that reframes molecular fragmentation as a dynamic Q-learning-based "vocabulary selection" problem, optimizing fragmentation and generation concurrently. Additionally, an agentic AI system engages in conversational feedback with domain experts to refine drug optimization objectives, progressively learning domain knowledge to automate the tuning process, ultimately transitioning from human-supervised to fully autonomous (Agent-Agent) optimization.</p>
                </section>

                <section class="paper-section">
                    <h2>Key Findings</h2>
                    <p>In real-world cancer drug discovery experiments, FRAGMENTA's Human-Agent configuration identified almost double the number of high-scoring molecules compared to baseline methods. The fully autonomous Agent-Agent system further demonstrated superior performance, outperforming traditional Human-Human tuning by effectively capturing expert intent and optimizing drug leads.</p>
                </section>
            </div>

            <section class="paper-section">
                <h2>Clinical Impact</h2>
                <p>FRAGMENTA has the potential to significantly reduce the time and cost associated with identifying and optimizing promising drug lead candidates, thereby accelerating the pipeline for developing new pharmaceuticals. This could lead to a quicker introduction of novel, more effective treatments for challenging diseases like cancer, directly benefiting patient outcomes.</p>
            </section>

            
            <section class="paper-section">
                <h2>Limitations</h2>
                <p>The abstract does not explicitly state limitations of the FRAGMENTA framework itself. However, it is presented as addressing and overcoming limitations inherent in existing methods, such as sparse datasets, heuristic fragmentation, and slow, indirect human-AI collaboration in model tuning.</p>
            </section>
            

            
            <section class="paper-section">
                <h2>Future Directions</h2>
                <p>The abstract implies future work focused on further developing the agentic AI system's ability to progressively learn and internalize domain knowledge, enabling it to fully automate model tuning and objective refinement. This trajectory aims to minimize or eliminate the need for direct intervention from AI engineers and potentially human domain experts in repetitive tuning tasks.</p>
            </section>
            

            <section class="paper-section">
                <h2>Medical Domains</h2>
                <div class="tags">
                    
                    <span class="tag">Oncology</span>
                    
                    <span class="tag">Pharmacology</span>
                    
                    <span class="tag">Medicinal Chemistry</span>
                    
                    <span class="tag">Drug Discovery</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Keywords</h2>
                <div class="tags">
                    
                    <span class="tag tag-keyword">Drug discovery</span>
                    
                    <span class="tag tag-keyword">Molecule generation</span>
                    
                    <span class="tag tag-keyword">Generative AI</span>
                    
                    <span class="tag tag-keyword">Fragment-based design</span>
                    
                    <span class="tag tag-keyword">Q-learning</span>
                    
                    <span class="tag tag-keyword">Agentic AI</span>
                    
                    <span class="tag tag-keyword">Lead optimization</span>
                    
                    <span class="tag tag-keyword">Cancer drug discovery</span>
                    
                </div>
            </section>

            <section class="paper-section">
                <h2>Abstract</h2>
                <p class="abstract">Molecule generation using generative AI is vital for drug discovery, yet class-specific datasets often contain fewer than 100 training examples. While fragment-based models handle limited data better than atom-based approaches, existing heuristic fragmentation limits diversity and misses key fragments. Additionally, model tuning typically requires slow, indirect collaboration between medicinal chemists and AI engineers. We introduce FRAGMENTA, an end-to-end framework for drug lead optimization comprising: 1) a novel generative model that reframes fragmentation as a "vocabulary selection" problem, using dynamic Q-learning to jointly optimize fragmentation and generation; and 2) an agentic AI system that refines objectives via conversational feedback from domain experts. This system removes the AI engineer from the loop and progressively learns domain knowledge to eventually automate tuning. In real-world cancer drug discovery experiments, FRAGMENTA's Human-Agent configuration identified nearly twice as many high-scoring molecules as baselines. Furthermore, the fully autonomous Agent-Agent system outperformed traditional Human-Human tuning, demonstrating the efficacy of agentic tuning in capturing expert intent.</p>
            </section>

            

            
        </article>
    </main>

    <footer class="container">
        <p><a href="../index.html">‚Üê Back to all papers</a></p>
    </footer>
</body>
</html>